CD14~+HLA-DR~(low/-)髓系来源抑制性细胞在弥漫大B细胞淋巴瘤中的预后价值
|
摘要
目的:探讨髓系来源抑制性细胞(MDSC)在弥漫大B细胞淋巴瘤(DLBCL)患者预后中的作用。方法:收集52例初诊DLBCL患者和30例健康志愿者外周血,以CD14~+HLA-DR~(low/-)作为MDSC的免疫标记,结合相关临床病理资料分析MDSC在DLBCL预后中的作用。结果:初诊DLBCL患者外周血MDSC水平相比对照组明显升高(P<0.01)。MDSC在DLBCL患者中表达与临床分期、乳酸脱氢酶(LDH)水平及IPI评分相关(P<0.01),与性别、年龄、有无B症状未见明显相关性。单因素分析结果提示,临床分期、血清LDH水平、IPI评分及MDSC水平是影响总生存(OS)不良因素。多因素分析结果提示,IPI评分和MDSC水平是影响患者OS的独立危险因素。结论:MDSC可作为评估DLBCL患者预后的重要指标,有助于评估患者机体免疫与肿瘤微环境的情况。
Objective: To investigate the role of myeloid-derived suppressor cells(MDSC) in the prognosis of patients with diffuse large B cell lymphoma(DLBCL). Methods: The peripheral blood of 52 DLBCL patients and 30 healthy volunteers was collected. The CD14~+HLA-DR~(low/-) was used as the immune marker for MDSC. The role of MDSC in the prognosis of DLBCL patients was analyzed by combination with the related clinicopathological data. Results: The proportion of MDSC in peripheral blood of newly diagnosed DLBCL patients increased significantly(P<0.01). The expression of MDSC in DLBCL patients was related with clinical staging, lactate dehydrogenase(LDH) level and IPI score(P<0.01). There was no significant correlation with sex, age, and B symptoms. Univariate analysis showed that the clinical stage, serum LDH level, IPI score and MDSC level were the adverse factors affecting the overall survival(OS).Multivariate analysis showed that IPI score and MDSC level were independent risk factors for OS in DLBCL patients.Conclusion: MDSC can be used as an important index to evaluate the prognosis of DLBCL patients, contributing to evaluate the immune and tumor microenvironment of DLBCL patients.
Objective: To investigate the role of myeloid-derived suppressor cells(MDSC) in the prognosis of patients with diffuse large B cell lymphoma(DLBCL). Methods: The peripheral blood of 52 DLBCL patients and 30 healthy volunteers was collected. The CD14~+HLA-DR~(low/-) was used as the immune marker for MDSC. The role of MDSC in the prognosis of DLBCL patients was analyzed by combination with the related clinicopathological data. Results: The proportion of MDSC in peripheral blood of newly diagnosed DLBCL patients increased significantly(P<0.01). The expression of MDSC in DLBCL patients was related with clinical staging, lactate dehydrogenase(LDH) level and IPI score(P<0.01). There was no significant correlation with sex, age, and B symptoms. Univariate analysis showed that the clinical stage, serum LDH level, IPI score and MDSC level were the adverse factors affecting the overall survival(OS).Multivariate analysis showed that IPI score and MDSC level were independent risk factors for OS in DLBCL patients.Conclusion: MDSC can be used as an important index to evaluate the prognosis of DLBCL patients, contributing to evaluate the immune and tumor microenvironment of DLBCL patients.
引文
1 Jia Y,Sun C,Liu Z,et al.Primary breast diffuse large B-cell lymphoma:a population-based study from 1975 to 2014.Oncotarget,2018;9(3):3956-3967.
2 Ganesan P,Sagar TG,Kannan K,et al.Long-term outcome of diffuse large B-cell lymphoma:Impact of biosimilar rituximab and radiation.Indian J Cancer,2017;54(2):430-435.
3 Wang ZT,Zhang LL,Wang HP,et al.Tumor-induced CD14+HLA-DR(-/low)myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.Cancer Immunol Immunother,2015;64(3):389-399.
4 Wei TF,Zhang J,Qin YH,et al.Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in nonsmall-cell lung cancer patients.Am J Cancer Res,2015;5(7):2190-2201.
5王馨辰,丁凯阳,王晓秋,等.RIP2在弥漫大B细胞淋巴瘤中的表达及预后意义.中国实验血液学杂志,2018;26(1):166-170.
6 De Sanctis F,Bronte V,Ugel S.Tumor-induced myeloid-derived suppressor cells.Microbiol Spectr,2016;4(3).doi:10.1128/microbiolspec.
7 Baniyash M.Myeloid-derived suppressor cells as intruders and targets:clinical implications in cancer therapy.Cancer Immunol Immunother,2016;65(7):857-867.
8 Mizukoshi E,Yamashita T,Arai K,et al.Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.Cancer Immunol Immunother,2016;65(6):715-725.
9 Huang HT,Zhang GB,Li GB,et al.Circulating CD14(+)HLA-DR(-/low)myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC.Tumour Biol,2015;36(10):7987-7996.
10 Gonda K,Shibata M,Ohtake T,et al.Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses,malnutrition,inflammation,and poor prognosis in patients with breast cancer.Oncol Lett,2017;14(2):1766-1774.
11 Wu CY,Wu XY,Liu XN,et al.Prognostic significance of monocytes and monocytic myeloid-derived suppressor cells in diffuse large B-cell lymphoma treated with R-CHOP.Cell Physiol Biochem,2016;39(2):521-530.
2 Ganesan P,Sagar TG,Kannan K,et al.Long-term outcome of diffuse large B-cell lymphoma:Impact of biosimilar rituximab and radiation.Indian J Cancer,2017;54(2):430-435.
3 Wang ZT,Zhang LL,Wang HP,et al.Tumor-induced CD14+HLA-DR(-/low)myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.Cancer Immunol Immunother,2015;64(3):389-399.
4 Wei TF,Zhang J,Qin YH,et al.Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in nonsmall-cell lung cancer patients.Am J Cancer Res,2015;5(7):2190-2201.
5王馨辰,丁凯阳,王晓秋,等.RIP2在弥漫大B细胞淋巴瘤中的表达及预后意义.中国实验血液学杂志,2018;26(1):166-170.
6 De Sanctis F,Bronte V,Ugel S.Tumor-induced myeloid-derived suppressor cells.Microbiol Spectr,2016;4(3).doi:10.1128/microbiolspec.
7 Baniyash M.Myeloid-derived suppressor cells as intruders and targets:clinical implications in cancer therapy.Cancer Immunol Immunother,2016;65(7):857-867.
8 Mizukoshi E,Yamashita T,Arai K,et al.Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.Cancer Immunol Immunother,2016;65(6):715-725.
9 Huang HT,Zhang GB,Li GB,et al.Circulating CD14(+)HLA-DR(-/low)myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC.Tumour Biol,2015;36(10):7987-7996.
10 Gonda K,Shibata M,Ohtake T,et al.Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses,malnutrition,inflammation,and poor prognosis in patients with breast cancer.Oncol Lett,2017;14(2):1766-1774.
11 Wu CY,Wu XY,Liu XN,et al.Prognostic significance of monocytes and monocytic myeloid-derived suppressor cells in diffuse large B-cell lymphoma treated with R-CHOP.Cell Physiol Biochem,2016;39(2):521-530.